How Does Danaher Make its Money?
Danaher is a global life sciences and diagnostics company that designs, manufactures, and sells instruments, consumables, software, and services used by scientists, researchers, and clinicians to develop drugs, diagnose diseases, and ensure safety in food and water. Following the 2023 spin-off of its environmental and applied solutions business (now Veralto), Danaher is a pure-play life sciences company organized around three segments: Biotechnology, Life Sciences, and Diagnostics.
Danaher is renowned for the Danaher Business System (DBS) — a proprietary set of lean management tools and continuous improvement processes derived from the Toyota Production System. DBS drives operational excellence across every acquisition and business unit, creating a compounding improvement engine that has made Danaher one of the best-performing industrial conglomerates over the past 30 years.
Danaher (DHR) Business Model
Danaher operates in the life sciences sector. Below is a summary of Danaher’s revenue streams, how the company generates income, and the key financial metrics from its most recent annual report. This breakdown uses data from Danaher’s 2024 fiscal year filings with the SEC.
Danaher Competitors
Danaher’s key competitors and comparable public companies include Abbott, Eli Lilly, and Pfizer. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Danaher stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Biotechnology | $8.4B | $7.8B | +7.7% |
| Life Sciences | $7.1B | $6.8B | +4.4% |
| Diagnostics | $8.2B | $8.4B | -2.4% |
| Total Revenue | $23.7B | $23.0B | +3.0% |
Biotechnology — 35% of Revenue
The Biotechnology segment (primarily Cytiva, acquired via the $21B GE Biopharma deal in 2020) provides the equipment, consumables, and services used to manufacture biologic drugs — monoclonal antibodies, cell and gene therapies, mRNA vaccines, and other large-molecule drugs:
- Bioprocessing equipment: Bioreactors, filtration systems, chromatography columns, and single-use technologies used in drug manufacturing
- Consumables: Filters, tubing, bags, and media that are replaced with each production batch — creating a high-margin, recurring revenue stream
- Services: Validation, installation, maintenance, and training for bioprocessing facilities
This segment experienced a pandemic-era boom (COVID vaccine production) followed by a significant destocking correction in 2023 as customers drew down inflated inventories. By 2024, the destocking largely ended and organic growth returned.
Life Sciences — 30% of Revenue
The Life Sciences segment provides instruments, reagents, and software for scientific research and drug discovery:
- Beckman Coulter Life Sciences: Centrifuges, flow cytometers, particle characterizers, and liquid handlers for research labs
- Leica Microsystems: Advanced microscopes for materials science, clinical pathology, and life sciences research
- SCIEX: Mass spectrometers and separation science instruments for pharmaceutical, clinical, and food safety testing
- Pall Life Sciences: Filtration and purification technologies for lab and industrial applications
Revenue is driven by R&D spending at pharmaceutical companies, universities, and government labs — a market that grows 4-6% annually over time.
Diagnostics — 35% of Revenue
The Diagnostics segment provides instruments and tests used in hospitals, reference labs, and physician offices to diagnose diseases:
- Beckman Coulter Diagnostics: Automated clinical laboratory instruments and assays for chemistry, immunoassay, hematology, and urinalysis — one of the “Big 3” clinical diagnostics platforms globally alongside Roche and Abbott
- Cepheid: Rapid molecular diagnostics. The GeneXpert platform provides near-patient testing for respiratory infections, STIs, oncology, and hospital-acquired infections. GeneXpert has an installed base of 70,000+ systems and a menu of 30+ tests
- Radiometer: Blood gas analysis, transcutaneous monitoring, and immunoassay testing at the point of care
Diagnostics revenue declined slightly in 2024 as COVID testing volumes continued to normalize, offset by growth in non-respiratory Cepheid tests and core lab instruments.
Income Statement Overview
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $23.7B | $23.0B |
| Cost of Revenue | $10.4B | $10.3B |
| Gross Profit | $13.3B | $12.7B |
| Operating Expenses | $6.8B | $6.6B |
| Operating Income | $6.5B | $6.1B |
| Net Income | $4.5B | $4.3B |
Key Financial Metrics
- Gross Margin: 56.1% — Excellent, reflecting the high-value, consumables-heavy nature of Danaher’s product mix. Recurring consumables and services account for ~75% of revenue and carry higher margins than instrument sales.
- Operating Margin: 27.4% — Strong and expanding as DBS drives continuous improvement. Danaher targets 30%+ operating margins over the cycle through mix shift and productivity.
- Revenue Growth: +3.0% — Modest headline growth reflects the tail end of post-pandemic normalization. Core (organic) growth was approximately +4%, with Biotechnology returning to mid-single-digit growth.
- Net Income: $4.5B — Solid profitability supported by recurring revenue streams and disciplined cost management.
- Free Cash Flow Conversion: ~130% of net income — Danaher consistently converts more than 100% of net income into free cash flow, a hallmark of its capital-light, consumables-driven model.
Is Danaher Profitable?
Yes, Danaher is highly profitable. The company reported net income of $4.5B on total revenue of $23.7B. With a gross margin of 56.1% and operating margin of 27.4%, Danaher demonstrates strong life sciences-sector profitability. The Danaher Business System drives consistently above-peer margins and free cash flow conversion.
Where Does Danaher Spend its Money?
- Cost of Goods Sold (~$10.4B): Manufacturing costs for instruments, consumables, and reagents across ~100 global manufacturing sites.
- R&D (~$2.0B): Developing next-generation instruments, diagnostic tests, and bioprocessing technologies. Key priorities include new Cepheid test menu expansion, connected instruments, and AI-powered analytics.
- SG&A (~$4.8B): Global sales teams, field service engineers, marketing, and corporate overhead. Danaher operates in 60+ countries with ~63,000 employees.
- Capital Expenditure (~$1.0B): Relatively low, reflecting the asset-light nature of instrument and consumables manufacturing.
- Acquisitions: Danaher’s core strategy has been acquiring well-positioned life sciences businesses and improving them with DBS. After the massive Cytiva (2020) and Abcam (~$5.7B, 2023) deals, the M&A pipeline is focused on bolt-on acquisitions in attractive niches.
- Shareholder Returns (~$1.5B): Dividends (~$0.7B) plus modest buybacks. Danaher prioritizes M&A over buybacks but maintains a growing dividend.
What to Watch
- Bioprocessing recovery — The post-COVID destocking headwind dragged down Biotechnology growth in 2023. The return to normalized ordering patterns and the underlying 8-10% growth in biologic drug manufacturing are the biggest near-term catalysts.
- Cepheid menu expansion — Cepheid’s GeneXpert is the most widely installed molecular diagnostics platform in the world. Each new test added to the menu drives incremental consumable revenue across the 70,000+ installed base. Respiratory panel, oncology, and hospital-acquired infection tests are key growth drivers.
- M&A pipeline — Danaher’s long-term value creation comes from acquiring, integrating, and improving businesses. The company has $15-20B+ in acquisition capacity. The next large deal could define Danaher’s next growth chapter.
- China exposure — Approximately 15% of revenue comes from China. Government anti-corruption campaigns, local competitor favoritism, and geopolitical tensions have created uncertainty in this market.
- Margin expansion to 30%+ — Danaher targets a 30%+ operating margin over the cycle through mix shift toward higher-margin consumables and software, plus DBS-driven productivity. Achieving this would unlock significant earnings growth even on modest revenue growth.
Danaher (DHR) Financial Summary
Danaher (DHR) is a life sciences company that generated $23.7B in total revenue in fiscal year 2024. Revenue grew +3.0% year-over-year. The company earned $4.5B in net income, making it highly profitable. For a deeper look at Danaher’s revenue breakdown, business segments, and financial performance, review the detailed analysis above.